NASDAQ$ZBIO
Zenas Biopharma Inc · Q2 2025 earnings
Q2 2025 earnings ·
Briefing
Zenas BioPharma reported Q2 2025, net loss of $52.2M, diluted EPS of $-1.25.
For Q2 2025, Zenas BioPharma reported a net loss of $52.2M, diluted EPS was $-1.25. The filing discusses segment trends, liquidity, and management outlook for upcoming periods.
- Net loss $52.2M.
- Diluted EPS $-1.25.
- Zenas BioPharma highlights operating priorities and capital allocation.
Headline financials
Revenue & EPS history
Zenas Biopharma Inc · Revenue · Quarterly
$0
Forward guidance
The release discusses Zenas BioPharma's outlook, capital allocation, and key risks for upcoming quarters, including guidance ranges or operating priorities where disclosed.
Tailwinds
- Zenas BioPharma cites demand and execution supporting the near-term outlook.
- Liquidity and balance-sheet capacity support operations and shareholder returns.
Headwinds
- GAAP profitability remained under pressure in Q2 2025.
- Macro, input costs, and FX may pressure margins quarter to quarter.
- Segment mix and one-time items can affect comparability versus prior periods.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 4 quarterly earnings reports · overlaid with Q2 2025
+4.3%
Avg return
Earnings day
+3.2%
Avg return
5 days after
+3.2%
Avg return
30 days after
80%
4 / 5 earnings
Positive
+12.2%
Q1 2025
Best reaction
-3.1%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +3.9% | -11.7% | +3.0% | |
| Q3 2025 | +1.7% | +1.9% | +15.3% | |
| Q2 2025 | +6.7% | +12.8% | +35.3% | |
| Q1 2025 | +12.2% | +32.3% | +19.0% | |
| Q3 2024 | -3.1% | -19.6% | -56.5% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro